Does Ozempic Damage Your Liver? What the Evidence Actually Shows

The most definitive evidence on semaglutide and liver health comes from the ESSENCE trial, a phase 3 clinical trial published in the New England Journal of Medicine in May 2025, involving 800 participants across 37 countries.

The trial was specifically designed to test semaglutide in patients who already had established liver disease — MASH (metabolic dysfunction-associated steatohepatitis) with significant liver fibrosis. These were patients with the most reason to be concerned about drug effects on the liver.

The safety data was unambiguous: there were no treatment discontinuations due to liver enzyme elevations across the entire semaglutide treatment arm. This is the most direct clinical evidence available that semaglutide, at therapeutic doses, does not cause liver injury even in patients with pre-existing significant liver disease.

Beyond safety, the efficacy data showed the opposite of liver damage. Among patients taking semaglutide 2.4mg weekly, 62.9% achieved resolution of MASH without worsening of fibrosis — compared to 34.3% on placebo. Semaglutide is not damaging the liver. It is repairing it.

If Ozempic does not cause liver damage, why do some patients experience elevated ALT and AST levels after starting the medication?

The answer is rapid weight loss — not the medication itself.

When weight loss occurs quickly — more than 1–1.5kg per week, which can happen in the early months on Ozempic — the body mobilises fat stores rapidly from adipose tissue throughout the body, including visceral fat around the abdominal organs. This process temporarily increases the delivery of free fatty acids to the liver. The liver processes and clears this fat, but during periods of very rapid mobilisation, the liver can become temporarily overloaded, producing a transient rise in liver enzymes.

This is sometimes called "steatohepatitis of rapid weight loss" and is a recognised phenomenon in any significant weight loss intervention — whether medication, very low calorie diet, or bariatric surgery. The elevation is generally self-limiting. As weight loss stabilises to a more gradual rate, the liver enzymes typically return to normal or continue to improve as overall liver fat reduces.

Importantly, this temporary elevation is fundamentally different from the liver enzyme elevation seen in viral hepatitis, alcohol-related liver disease, or drug-induced liver injury. The mechanism, the trajectory, and the clinical implications are entirely different.

While transient enzyme elevations during rapid weight loss are generally benign, there are circumstances where liver enzyme changes on Ozempic should prompt further investigation:

Elevations that do not resolve within 3 months. If ALT or AST remains elevated beyond the initial rapid weight loss phase, this warrants investigation for other causes — including pre-existing MASLD, viral hepatitis, autoimmune liver disease, or alcohol use.

Elevations more than 3 times the upper limit of normal. ALT above 168 U/L (for men) or 57 U/L (for women), or AST above 120 U/L, at any point during therapy should prompt clinical review.

New symptoms. Fatigue, right upper quadrant discomfort, jaundice, or dark urine occurring after starting Ozempic should be evaluated promptly.

Pre-existing liver disease. Patients with known liver disease — including established MASLD, hepatitis B or C, autoimmune hepatitis, or any history of liver fibrosis — should have baseline liver function established before starting Ozempic and be monitored throughout therapy.

One scenario that is clinically important and often overlooked: a patient starts Ozempic, has blood tests a few months later, and finds their liver enzymes are elevated. They — and sometimes their GP — assume Ozempic is damaging the liver. But in many cases, the reality is different.

The patient had undiagnosed MASLD before starting Ozempic. The elevated enzymes reflect the pre-existing disease, not drug-induced injury. Starting Ozempic simply prompted the first blood test in years that looked carefully at liver function — and uncovered a disease that was already there.

This scenario is clinically important because it changes the management entirely. If the elevated enzymes are from pre-existing MASLD, stopping Ozempic is likely the wrong decision. Semaglutide is one of the few treatments with evidence of actually improving MASLD. Continuing therapy while monitoring the response is often the appropriate path — in consultation with a hepatologist or gastroenterologist.

This is precisely why baseline FIB-4 testing before starting any GLP-1 medication is recommended in current Australian guidelines.

If your FIB-4 score is in the indeterminate range (1.3–2.67), or if you have elevated liver enzymes on Ozempic and want to understand what is happening in your liver, a liver elastography scan provides the most accurate non-invasive assessment available.

The scan measures liver stiffness (kPa) — a proxy for fibrosis and scarring — and liver fat content (CAP score in dB/m). It takes 10–15 minutes, involves no radiation, no injection, and no hospitalisation. Results are available immediately.

A normal liver stiffness reading (below 8 kPa) in the context of elevated liver enzymes is strongly reassuring — it indicates that even if some inflammation is present, there is no significant fibrosis or scarring. A reading above 12–13 kPa warrants specialist review.

Find a liver elastography clinic near you →